- Home
- SANA vs VALN Comparison
SANA vs VALN Comparison
Compare SANA & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SANA
- VALN
- Stock Information
- Founded
- SANA 2018
- VALN 2012
- Country
- SANA United States
- VALN France
- Employees
- SANA N/A
- VALN N/A
- Industry
- SANA Medicinal Chemicals and Botanical Products
- VALN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SANA Health Care
- VALN Health Care
- Exchange
- SANA Nasdaq
- VALN Nasdaq
- Market Cap
- SANA 983.4M
- VALN 820.0M
- IPO Year
- SANA 2021
- VALN 2021
- Fundamental
- Price
- SANA $4.90
- VALN $9.13
- Analyst Decision
- SANA Strong Buy
- VALN Strong Buy
- Analyst Count
- SANA 6
- VALN 4
- Target Price
- SANA $8.00
- VALN $15.75
- AVG Volume (30 Days)
- SANA 6.7M
- VALN 48.5K
- Earning Date
- SANA 11-11-2025
- VALN 11-20-2025
- Dividend Yield
- SANA N/A
- VALN N/A
- EPS Growth
- SANA N/A
- VALN N/A
- EPS
- SANA N/A
- VALN N/A
- Revenue
- SANA N/A
- VALN $230,566,060.00
- Revenue This Year
- SANA N/A
- VALN $15.69
- Revenue Next Year
- SANA N/A
- VALN $22.15
- P/E Ratio
- SANA N/A
- VALN N/A
- Revenue Growth
- SANA N/A
- VALN 25.47
- 52 Week Low
- SANA $1.26
- VALN $3.62
- 52 Week High
- SANA $7.30
- VALN $12.25
- Technical
- Relative Strength Index (RSI)
- SANA 59.91
- VALN 36.67
- Support Level
- SANA $5.12
- VALN $10.08
- Resistance Level
- SANA $5.90
- VALN $10.55
- Average True Range (ATR)
- SANA 0.56
- VALN 0.26
- MACD
- SANA -0.02
- VALN -0.19
- Stochastic Oscillator
- SANA 49.89
- VALN 0.00
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.